CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies.
Steven N QuayleNatasha GirgisDharma R ThapaZohra MerazgaMelissa M KempAlex HistedFan ZhaoMiguel MoretaPaige RuthardtSandrine HulotAlyssa NelsonLauren D KraemerDominic R BealLuke WittJessica RyabinJonathan SorianoMark HaydockEmily SpauldingJohn F RossPeter A KienerSteven AlmoRodolfo ChaparroRonald SeidelAnish SuriSaso CemerskiKenneth J PientaMary Ellen SimcoxPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Consistent with its design, CUE-101 demonstrates selective expansion of an HPV16 E711-20-specific population of cytotoxic CD8+ T cells, a favorable safety profile, and in vitro and in vivo evidence supporting its potential for clinical efficacy in an ongoing phase I trial (NCT03978689).